<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982150</url>
  </required_header>
  <id_info>
    <org_study_id>ALS-TAL-201-OL</org_study_id>
    <nct_id>NCT00982150</nct_id>
  </id_info>
  <brief_title>Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>ALSTAR OL</acronym>
  <official_title>A Multinational, Multicenter, Open Label Phase to Assess Tolerability and Safety of Talampanel 50mg Tid in Subjects With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open label treatment extension phase in patients with ALS who have previously
      participated in the double blind, placebo-controlled ALS-TAL-201 study. This study will make
      talampanel treatment available to all subjects who completed the double blind
      placebo-controlled phase of ALS-TAL-201 study and where the investigator and patient consider
      it to be in the patient's interest to receive talampanel 50mg three times daily (tid). It
      will also enable the exploration of long-term safety and tolerability of talampanel 50mg tid.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Core study unsuccessful
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALSFRS-R</measure>
    <time_frame>every 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital Signs, ECG, Adverse Event Reports</measure>
    <time_frame>every 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">446</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Talampanel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Talampanel 50mg tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talampanel</intervention_name>
    <description>50mg capsules tid</description>
    <arm_group_label>Talampanel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have completed 52 weeks of treatment of the double blind
             placebo-controlled phase of ALS-TAL-201.

          -  Women must be postmenopausal, surgically sterile, or using adequate birth control
             methods.

          -  Patients must be willing and able to give written informed consent prior to performing
             any open-label study procedures.

        Exclusion Criteria:

          -  Patients with ECG signs of Brugada syndrome and/ or complete or incomplete Right
             Bundle Branch Block

          -  Patients using any of the following:

               -  Chronic use of lithium carbonate

               -  Chronic use of mecasermin (rhIGF-1)

               -  Chronic use of minocycline

               -  Chronic use of more than 600mg/day coenzyme Q10

               -  Chronic use of any marketed drug, if its use was not clearly indicated for any
                  underlying medical condition other than ALS (symptomatic drugs for ALS and
                  supplements allowed)

          -  Patients participating in any other investigational drug study and use of any other
             investigational drug

          -  Patients taking drugs that may interact with Talampanel

          -  Females who are pregnant or nursing.

          -  Females of child-bearing potential who do not practice medically acceptable methods of
             contraception.

          -  Any condition of the patient which the investigator feels may interfere with
             participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2009</study_first_posted>
  <disposition_first_submitted>August 16, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 16, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 26, 2013</disposition_first_posted>
  <last_update_submitted>August 16, 2013</last_update_submitted>
  <last_update_submitted_qc>August 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Talampanel</keyword>
  <keyword>Open-Label Study</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

